Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 322

1.

Bilateral Subthalamic Nucleus Deep Brain Stimulation in Elderly Patients With Parkinson Disease: A Case-Control Study.

Mitchell KT, Younce JR, Norris SA, Tabbal SD, Dowling JL, Rich KM, Perlmutter JS, Ushe M.

Oper Neurosurg (Hagerstown). 2020 Apr 7. pii: opaa049. doi: 10.1093/ons/opaa049. [Epub ahead of print]

PMID:
32259239
2.

A Clinical Trial of Isradipine: What Went Wrong?

Maiti B, Perlmutter JS.

Ann Intern Med. 2020 Mar 31. doi: 10.7326/M20-1023. [Epub ahead of print] No abstract available.

PMID:
32227234
3.

Defining research priorities in dystonia.

Lungu C, Ozelius L, Standaert D, Hallett M, Sieber BA, Swanson-Fisher C, Berman BD, Calakos N, Moore JC, Perlmutter JS, Pirio Richardson SE, Saunders-Pullman R, Scheinfeldt L, Sharma N, Sillitoe R, Simonyan K, Starr PA, Taylor A, Vitek J; participants and organizers of the NINDS Workshop on Research Priorities in Dystonia.

Neurology. 2020 Mar 24;94(12):526-537. doi: 10.1212/WNL.0000000000009140. Epub 2020 Feb 25. Review.

PMID:
32098856
4.

APOE genotype regulates pathology and disease progression in synucleinopathy.

Davis AA, Inman CE, Wargel ZM, Dube U, Freeberg BM, Galluppi A, Haines JN, Dhavale DD, Miller R, Choudhury FA, Sullivan PM, Cruchaga C, Perlmutter JS, Ulrich JD, Benitez BA, Kotzbauer PT, Holtzman DM.

Sci Transl Med. 2020 Feb 5;12(529). pii: eaay3069. doi: 10.1126/scitranslmed.aay3069.

PMID:
32024799
5.

Postural Directionality and Head Tremor in Cervical Dystonia.

Chen Q, Vu JP, Cisneros E, Benadof CN, Zhang Z, Barbano RL, Goetz CG, Jankovic J, Jinnah HA, Perlmutter JS, Appelbaum MI, Stebbins GT, Comella CL, Peterson DA.

Tremor Other Hyperkinet Mov (N Y). 2020 Jan 20;10. doi: 10.7916/tohm.v0.745. eCollection 2020.

6.

Little Change in Functional Brain Networks Following Acute Levodopa in Drug-Naïve Parkinson's Disease.

White RL 3rd, Campbell MC, Yang D, Shannon W, Snyder AZ, Perlmutter JS.

Mov Disord. 2020 Mar;35(3):499-503. doi: 10.1002/mds.27942. Epub 2019 Dec 19.

PMID:
31854465
7.

Psychometric properties and responsiveness of Neuro-QoL Cognitive Function in persons with Huntington disease (HD).

Carlozzi NE, Boileau NR, Paulsen JS, Downing NR, Ready R, Perlmutter JS, Cella D, Chou KL, McCormack MK, Barton S, Lai JS.

Qual Life Res. 2019 Dec 18. doi: 10.1007/s11136-019-02391-7. [Epub ahead of print]

PMID:
31853881
8.

Proteinopathy and longitudinal changes in functional connectivity networks in Parkinson disease.

Campbell MC, Jackson JJ, Koller JM, Snyder AZ, Kotzbauer PT, Perlmutter JS.

Neurology. 2020 Feb 18;94(7):e718-e728. doi: 10.1212/WNL.0000000000008677. Epub 2019 Dec 18.

PMID:
31852813
9.

Cognitive correlates of cerebellar resting-state functional connectivity in Parkinson disease.

Maiti B, Koller JM, Snyder AZ, Tanenbaum AB, Norris SA, Campbell MC, Perlmutter JS.

Neurology. 2020 Jan 28;94(4):e384-e396. doi: 10.1212/WNL.0000000000008754. Epub 2019 Dec 17.

PMID:
31848257
10.

Risk of spread in adult-onset isolated focal dystonia: a prospective international cohort study.

Berman BD, Groth CL, Sillau SH, Pirio Richardson S, Norris SA, Junker J, Brüggemann N, Agarwal P, Barbano RL, Espay AJ, Vizcarra JA, Klein C, Bäumer T, Loens S, Reich SG, Vidailhet M, Bonnet C, Roze E, Jinnah HA, Perlmutter JS.

J Neurol Neurosurg Psychiatry. 2020 Mar;91(3):314-320. doi: 10.1136/jnnp-2019-321794. Epub 2019 Dec 17.

11.

Striatal DAT SPECT: Caveat Emptor!

Perlmutter JS, Stoessl AJ.

Mov Disord. 2019 Oct;34(10):1430-1432. doi: 10.1002/mds.27811. No abstract available.

PMID:
31769089
12.

Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Yang P, Perlmutter JS, Benzinger TLS, Morris JC, Xu J.

Ageing Res Rev. 2020 Jan;57:100994. doi: 10.1016/j.arr.2019.100994. Epub 2019 Nov 22. Review.

13.

The impact of dopamine D2-like agonist/antagonist on [18F]VAT PET measurement of VAChT in the brain of nonhuman primates.

Liu H, Luo Z, Gu J, Su Y, Flores H, Parsons SM, Zhou Y, Perlmutter JS, Tu Z.

Eur J Pharm Sci. 2020 Feb 15;143:105152. doi: 10.1016/j.ejps.2019.105152. Epub 2019 Nov 15.

PMID:
31740395
14.

Detecting associations between intact connectomes and clinical covariates using recursive partitioning object-oriented data analysis.

Yang D, Deych E, Shands B, Campbell MC, Perlmutter JS, Petersen S, Schlaggar BL, Shannon W.

Stat Med. 2019 Dec 20;38(29):5486-5496. doi: 10.1002/sim.8374. Epub 2019 Oct 25.

PMID:
31650580
15.

The interactions of dopamine and oxidative damage in the striatum of patients with neurodegenerative diseases.

Li H, Yang P, Knight W, Guo Y, Perlmutter JS, Benzinger TLS, Morris JC, Xu J.

J Neurochem. 2020 Jan;152(2):235-251. doi: 10.1111/jnc.14898. Epub 2019 Nov 4.

16.

How different aspects of motor dysfunction influence day-to-day function in huntington's disease.

Carlozzi NE, Schilling SG, Boileau NR, Chou KL, Perlmutter JS, Frank S, McCormack MK, Stout JC, Paulsen JS, Lai JS, Dayalu P.

Mov Disord. 2019 Dec;34(12):1910-1914. doi: 10.1002/mds.27866. Epub 2019 Oct 14.

PMID:
31609508
17.

Neuroinflammation and Myelin Status in Alzheimer's Disease, Parkinson's Disease, and Normal Aging Brains: A Small Sample Study.

Han F, Perrin RJ, Wang Q, Wang Y, Perlmutter JS, Morris JC, Benzinger TLS, Xu J.

Parkinsons Dis. 2019 Jul 4;2019:7975407. doi: 10.1155/2019/7975407. eCollection 2019.

18.

Low Back Pain--Related Disability in Parkinson Disease: Impact on Functional Mobility, Physical Activity, and Quality of Life.

Duncan RP, Van Dillen LR, Garbutt JM, Earhart GM, Perlmutter JS.

Phys Ther. 2019 Oct 28;99(10):1346-1353. doi: 10.1093/ptj/pzz094.

PMID:
31343700
19.

Automated production of a sphingosine-1 phosphate receptor 1 (S1P1) PET radiopharmaceutical [11C]CS1P1 for human use.

Luo Z, Gu J, Dennett RC, Gaehle GG, Perlmutter JS, Chen DL, Benzinger TLS, Tu Z.

Appl Radiat Isot. 2019 Oct;152:30-36. doi: 10.1016/j.apradiso.2019.06.029. Epub 2019 Jun 20.

PMID:
31280104
20.

End-of-life measures in Huntington disease: HDQLIFE Meaning and Purpose, Concern with Death and Dying, and End of Life Planning.

Carlozzi NE, Boileau NR, Paulsen JS, Perlmutter JS, Lai JS, Hahn EA, McCormack MK, Nance MA, Cella D, Barton SK, Downing NR.

J Neurol. 2019 Oct;266(10):2406-2422. doi: 10.1007/s00415-019-09417-7. Epub 2019 Jun 12.

PMID:
31190171
21.

Development of a carbon-11 PET radiotracer for imaging TRPC5 in the brain.

Yu Y, Liang Q, Liu H, Luo Z, Hu H, Perlmutter JS, Tu Z.

Org Biomol Chem. 2019 Jun 5;17(22):5586-5594. doi: 10.1039/c9ob00893d.

PMID:
31115430
22.

Head tremor at disease onset: an ataxic phenotype of cervical dystonia.

Merola A, Dwivedi AK, Shaikh AG, Tareen TK, Da Prat GA, Kauffman MA, Hampf J, Mahajan A, Marsili L, Jankovic J, Comella CL, Berman BD, Perlmutter JS, Jinnah HA, Espay AJ.

J Neurol. 2019 Aug;266(8):1844-1851. doi: 10.1007/s00415-019-09341-w. Epub 2019 Apr 26.

PMID:
31028543
23.

Exercise and Parkinson Disease: Comparing Tango, Treadmill, and Stretching.

Rawson KS, McNeely ME, Duncan RP, Pickett KA, Perlmutter JS, Earhart GM.

J Neurol Phys Ther. 2019 Jan;43(1):26-32. doi: 10.1097/NPT.0000000000000245.

24.

Thalamic and ventricular volumes predict motor response to deep brain stimulation for Parkinson's disease.

Younce JR, Campbell MC, Perlmutter JS, Norris SA.

Parkinsonism Relat Disord. 2019 Apr;61:64-69. doi: 10.1016/j.parkreldis.2018.11.026. Epub 2018 Nov 28.

25.

Syntheses and in vitro biological evaluation of S1PR1 ligands and PET studies of four F-18 labeled radiotracers in the brain of nonhuman primates.

Luo Z, Han J, Liu H, Rosenberg AJ, Chen DL, Gropler RJ, Perlmutter JS, Tu Z.

Org Biomol Chem. 2018 Dec 5;16(47):9171-9184. doi: 10.1039/c8ob02609b.

26.

Emergent Functional Network Effects in Parkinson Disease.

Gratton C, Koller JM, Shannon W, Greene DJ, Maiti B, Snyder AZ, Petersen SE, Perlmutter JS, Campbell MC.

Cereb Cortex. 2019 Apr 1;29(4):1701. doi: 10.1093/cercor/bhy229. No abstract available.

PMID:
30418543
27.

Predictors of alcohol responsiveness in dystonia.

Junker J, Brandt V, Berman BD, Vidailhet M, Roze E, Weissbach A, Comella C, Malaty IA, Jankovic J, LeDoux MS, Berardelli A, Barbano R, Reich SG, Perlmutter JS, Jinnah HA, Brüggemann N.

Neurology. 2018 Nov 20;91(21):e2020-e2026. doi: 10.1212/WNL.0000000000006551. Epub 2018 Oct 19.

28.

PET Imaging in Movement Disorders.

Maiti B, Perlmutter JS.

Semin Nucl Med. 2018 Nov;48(6):513-524. doi: 10.1053/j.semnuclmed.2018.07.006. Epub 2018 Aug 16. Review.

29.

Radiosynthesis and evaluation of a fluorine-18 labeled radioligand targeting vesicular acetylcholine transporter.

Yue X, Luo Z, Liu H, Kaneshige K, Parsons SM, Perlmutter JS, Tu Z.

Bioorg Med Chem Lett. 2018 Nov 15;28(21):3425-3430. doi: 10.1016/j.bmcl.2018.09.030. Epub 2018 Sep 24.

30.

ESM-CT: a precise method for localization of DBS electrodes in CT images.

Milchenko M, Snyder AZ, Campbell MC, Dowling JL, Rich KM, Brier LM, Perlmutter JS, Norris SA.

J Neurosci Methods. 2018 Oct 1;308:366-376. doi: 10.1016/j.jneumeth.2018.09.009. Epub 2018 Sep 7.

31.

Validation of diffusion tensor imaging measures of nigrostriatal neurons in macaques.

Shimony JS, Rutlin J, Karimi M, Tian L, Snyder AZ, Loftin SK, Norris SA, Perlmutter JS.

PLoS One. 2018 Sep 5;13(9):e0202201. doi: 10.1371/journal.pone.0202201. eCollection 2018.

32.

Mapping movement, mood, motivation and mentation in the subthalamic nucleus.

Gourisankar A, Eisenstein SA, Trapp NT, Koller JM, Campbell MC, Ushe M, Perlmutter JS, Hershey T, Black KJ.

R Soc Open Sci. 2018 Jul 18;5(7):171177. doi: 10.1098/rsos.171177. eCollection 2018 Jul.

33.

Selective D2 receptor PET in manganese-exposed workers.

Criswell SR, Warden MN, Searles Nielsen S, Perlmutter JS, Moerlein SM, Sheppard L, Lenox-Krug J, Checkoway H, Racette BA.

Neurology. 2018 Sep 11;91(11):e1022-e1030. doi: 10.1212/WNL.0000000000006163. Epub 2018 Aug 10.

34.

Exploration of Sulfur-Containing Analogues for Imaging Vesicular Acetylcholine Transporter in the Brain.

Luo Z, Liu H, Jin H, Gu J, Yu Y, Kaneshige K, Perlmutter JS, Parsons SM, Tu Z.

ChemMedChem. 2018 Sep 19;13(18):1978-1987. doi: 10.1002/cmdc.201800411. Epub 2018 Aug 19.

35.

Suicidal Ideation Assessment in Individuals with Premanifest and Manifest Huntington Disease.

Wesson M, Boileau NR, Perlmutter JS, Paulsen JS, Barton SK, McCormack MK, Carlozzi NE.

J Huntingtons Dis. 2018;7(3):239-249. doi: 10.3233/JHD-180299.

36.

Consensus-Based Attributes for Identifying Patients With Spasmodic Dysphonia and Other Voice Disorders.

Ludlow CL, Domangue R, Sharma D, Jinnah HA, Perlmutter JS, Berke G, Sapienza C, Smith ME, Blumin JH, Kalata CE, Blindauer K, Johns M, Hapner E, Harmon A, Paniello R, Adler CH, Crujido L, Lott DG, Bansberg SF, Barone N, Drulia T, Stebbins G.

JAMA Otolaryngol Head Neck Surg. 2018 Aug 1;144(8):657-665. doi: 10.1001/jamaoto.2018.0644.

37.

Emergent Functional Network Effects in Parkinson Disease.

Gratton C, Koller JM, Shannon W, Greene DJ, Maiti B, Snyder AZ, Petersen SE, Perlmutter JS, Campbell MC.

Cereb Cortex. 2019 Jun 1;29(6):2509-2523. doi: 10.1093/cercor/bhy121. Erratum in: Cereb Cortex. 2019 Apr 1;29(4):1701.

PMID:
29878081
38.

Pleiotropic Effects of Variants in Dementia Genes in Parkinson Disease.

Ibanez L, Dube U, Davis AA, Fernandez MV, Budde J, Cooper B, Diez-Fairen M, Ortega-Cubero S, Pastor P, Perlmutter JS, Cruchaga C, Benitez BA.

Front Neurosci. 2018 Apr 10;12:230. doi: 10.3389/fnins.2018.00230. eCollection 2018.

39.

Agreement between clinician-rated versus patient-reported outcomes in Huntington disease.

Carlozzi NE, Boileau NR, Perlmutter JS, Chou KL, Stout JC, Paulsen JS, McCormack MK, Cella D, Nance MA, Lai JS, Dayalu P.

J Neurol. 2018 Jun;265(6):1443-1453. doi: 10.1007/s00415-018-8852-5. Epub 2018 Apr 23.

40.

Relationships Among Apathy, Health-Related Quality of Life, and Function in Huntington's Disease.

Fritz NE, Boileau NR, Stout JC, Ready R, Perlmutter JS, Paulsen JS, Quaid K, Barton S, McCormack MK, Perlman SL, Carlozzi NE; Huntington Disease Quality of Life Site Investigators and Coordinators, University of Michigan, University of Iowa, Indiana University, Johns Hopkins University, University of California, Rutgers University, Piscataway, Washington University, Struthers Parkinson’s Center, Cleveland Clinic Foundation, University of California, Northwestern University.

J Neuropsychiatry Clin Neurosci. 2018 Summer;30(3):194-201. doi: 10.1176/appi.neuropsych.17080173. Epub 2018 Mar 21.

41.

Pharmacokinetics and Toxicology of the Neuroprotective e,e,e-Methanofullerene(60)-63-tris Malonic Acid [C3] in Mice and Primates.

Hardt JI, Perlmutter JS, Smith CJ, Quick KL, Wei L, Chakraborty SK, Dugan LL.

Eur J Drug Metab Pharmacokinet. 2018 Oct;43(5):543-554. doi: 10.1007/s13318-018-0464-z.

42.

Physical therapy and deep brain stimulation in Parkinson's Disease: protocol for a pilot randomized controlled trial.

Duncan RP, Van Dillen LR, Garbutt JM, Earhart GM, Perlmutter JS.

Pilot Feasibility Stud. 2018 Feb 21;4:54. doi: 10.1186/s40814-018-0243-2. eCollection 2018.

43.

Quantitative, clinically relevant acoustic measurements of focal embouchure dystonia.

Morris AE, Norris SA, Perlmutter JS, Mink JW.

Mov Disord. 2018 Mar;33(3):449-458. doi: 10.1002/mds.27298. Epub 2018 Feb 20.

44.

In Vivo Characterization of Two 18F-Labeled PDE10A PET Radioligands in Nonhuman Primate Brains.

Liu H, Jin H, Luo Z, Yue X, Zhang X, Flores H, Su Y, Perlmutter JS, Tu Z.

ACS Chem Neurosci. 2018 May 16;9(5):1066-1073. doi: 10.1021/acschemneuro.7b00458. Epub 2018 Feb 19.

45.

7T MRI subthalamic nucleus atlas for use with 3T MRI.

Milchenko M, Norris SA, Poston K, Campbell MC, Ushe M, Perlmutter JS, Snyder AZ.

J Med Imaging (Bellingham). 2018 Jan;5(1):015002. doi: 10.1117/1.JMI.5.1.015002. Epub 2018 Jan 8.

46.

Kinetic modeling of [18 F]VAT, a novel radioligand for positron emission tomography imaging vesicular acetylcholine transporter in non-human primate brain.

Jin H, Yue X, Liu H, Han J, Flores H, Su Y, Parsons SM, Perlmutter JS, Tu Z.

J Neurochem. 2018 Mar;144(6):791-804. doi: 10.1111/jnc.14291. Epub 2018 Mar 25.

47.

Synthesis and in vitro characterization of a P2X7 radioligand [123I]TZ6019 and its response to neuroinflammation in a mouse model of Alzheimer disease.

Jin H, Han J, Resing D, Liu H, Yue X, Miller RL, Schoch KM, Miller TM, Perlmutter JS, Egan TM, Tu Z.

Eur J Pharmacol. 2018 Feb 5;820:8-17. doi: 10.1016/j.ejphar.2017.12.006. Epub 2017 Dec 7.

48.

A new measure for end of life planning, preparation, and preferences in Huntington disease: HDQLIFE end of life planning.

Carlozzi NE, Hahn EA, Frank SA, Perlmutter JS, Downing ND, McCormack MK, Barton S, Nance MA, Schilling SG; HDQLIFE Site Investigators and Coordinators.

J Neurol. 2018 Jan;265(1):98-107. doi: 10.1007/s00415-017-8677-7. Epub 2017 Nov 15.

49.

Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels.

Ibanez L, Dube U, Saef B, Budde J, Black K, Medvedeva A, Del-Aguila JL, Davis AA, Perlmutter JS, Harari O, Benitez BA, Cruchaga C.

BMC Neurol. 2017 Nov 15;17(1):198. doi: 10.1186/s12883-017-0978-z.

50.

ACR Appropriateness Criteria® Cranial Neuropathy.

Expert Panel on Neurologic Imaging:, Policeni B, Corey AS, Burns J, Conley DB, Crowley RW, Harvey HB, Hoang J, Hunt CH, Jagadeesan BD, Juliano AF, Kennedy TA, Moonis G, Pannell JS, Patel ND, Perlmutter JS, Rosenow JM, Schroeder JW, Whitehead MT, Cornelius RS.

J Am Coll Radiol. 2017 Nov;14(11S):S406-S420. doi: 10.1016/j.jacr.2017.08.035.

PMID:
29101981

Supplemental Content

Loading ...
Support Center